IP Verse

New Use - EP3038654

EP3038654

NOVARTIS
Application Number
EP14761702A
Filing Date
Aug 26, 2014
Status
Revoked
Oct 15, 2024
Grant Date
Oct 30, 2019
External Links
Slate, Register, Google Patents

Bibliography

The patent EP3038654B1 was granted to Novartis on Oct 30, 2019 following the initial filing on Aug 26, 2014 under the application number EP14761702A . The current legal status of the patent is Revoked.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ALFRED E TIEFENBACHERJul 30, 2020ADMISSIBLE
BETAPHARM ARZNEIMITTELJul 30, 2020ADMISSIBLE
KRKAJul 30, 2020ADMISSIBLE
POLPHARMAJul 30, 2020ADMISSIBLE
TEVA PHARMACEUTICALSJul 30, 2020ADMISSIBLE
KRAUS & LEDERER PARTGMBBJul 28, 2020ADMISSIBLE
ZENTIVAJul 23, 2020ADMISSIBLE
SYNTHONJul 17, 2020ADMISSIBLE
GENERICS UKJul 6, 2020ADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0443983
DESCRIPTIONUS5217996
DESCRIPTIONUS5399578
DESCRIPTIONWO03059345
DESCRIPTIONWO2007056546
DESCRIPTIONWO2009061713
DESCRIPTIONWO2014029848
INTERNATIONAL-SEARCH-REPORTUS2013158088
INTERNATIONAL-SEARCH-REPORTWO03059345
INTERNATIONAL-SEARCH-REPORTWO2007056546
OPPOSITIONEP2752189
OPPOSITIONUS2013158088
OPPOSITIONWO03059345
OPPOSITIONWO2007056546
OPPOSITIONWO2012027237

Non-Patent Literature (NPL) Citations (64) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- DORON ARONSON ET AL, "Novel therapies in acute and chronic heart failure", PHARMACOLOGY AND THERAPEUTICS, vol. 135, no. 1, doi:10.1016/J.PHARMTHERA.2012.03.002, ISSN 0163-7258, (2012), pages 1 - 17, (20120323), XP028503167
EXAMINATION- CHI HEEM WONG ET AL, "Estimation of clinical trial success rates and related parameters", BIOSTATISTICS, GB, (20190401), vol. 20, no. 2, doi:10.1093/biostatistics/kxx069, ISSN 1465-4644, pages 273 - 286, XP055604937
OPPOSITION- Anonymous, "Diovan (Valsartan) Tablets. FDA label. Reference ID: 3199353", Novartis Pharmaceuticals Corp., (20121001), pages 1 - 20, XP055780468-
OPPOSITION- Anonymous, "PARADIGM-HF trial stopped early for benefit", European Society of Cardiology The ESC ESC Press Office Press releases, (20040516), pages 1 - 4, European Society of Cardiology The ESC ESC Press Office Press releases, URL: https://www.escardio.org/The-ESC/Press-Office/Press-releases/PARADIGM-HF-trial-stopped-early-for-benefit, (20220117), XP055879620-
OPPOSITION- Anonymous, "Study NCT01035255 Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients with Chronic Heart Failure (PARADIGM-HF)", ClinicalTrials.gov, (20120503), pages 1 - 3, (20210607), XP055810892-
OPPOSITION- Carlsen Christian Malchau, Et Al, "Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study", European Journal of Heart Failure, (20120101), vol. 14, pages 240 - 247, XP055780120-
OPPOSITION- CHRONIC HEART FAILURE - National clinical guideline for diagnosis and management in primary and secondary care, (20100800), pages 1 - 153-
OPPOSITION- Crunkhorn Sarah, "Dual-acting combination meets heart failure end point", Nature Reviews, (20121001), vol. 11, page 740, XP055810895-
OPPOSITION- Cuculi Florim, Erne Paul, "Combined neutral endopeptidase inhibitors", Expert Opinion on Investigational Drugs, (20110215), vol. 20, no. 4, pages 457 - 463, XP055780113-
OPPOSITION- Doust Jenny, Et Al, "The Role of BNP Testing in Heart Failure", American Family Physician, (20060101), vol. 74, no. 11, pages 1894 - 1898, XP055780116-
OPPOSITION- Entresto advertising-
OPPOSITION- Gary Misan, Simone Rossi, Genevieve Gabb, Agnes Vitry, Fay Abbott, Richard Hill, Melissa Hughes, Eve Hurley,, Australian Medicines Handbook, (19980000), pages 2pp, 6-18 - 6-57, XP055767140-
OPPOSITION- Hegde Laxminarayan G, Et Al, "Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-Like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation In The Rat", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, (20110401), vol. 57, no. 4, pages 495 - 504, XP055780042-
OPPOSITION- Jordaan P, Et Al, "Changes in RAAS (renin angiotensin aldosterone system) biomarkers in stable chronic heart failure (HF) patients following short-term angiotensin receptor neprilysin inhibitor (ARNI) treatment", SA Heart Congress 2011, (20110101), page 236, XP055780447-
OPPOSITION- Julian Segura Jorge Salazar Luis M Ruilope, "Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition", EXPERT OPINION IN INVESTIGATIONAL DRUGS, GB, (20130701), vol. 22, no. 7, ISSN 0967-8298, pages 915 - 925, XP009174158-
OPPOSITION- KOBALAVA et al., "Abstract 19378: First experience with concomitant AT 1 and neprilysin (NEP 24.11) inhibition with LCZ696 in patients with chronic heart failure", Circulation, (20100000), vol. 122, page A19378, XP009190562-
OPPOSITION- Kobalava Z. , Averkov O. , Meray I. , Alexandriya L. , Moiseev V. , Albrecht D. , Feng A. , Chandra P. , Jordaan P.J., "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: Effect on ANP, BNP, NT-proBNP and cGMP", European Heart Journal, (20110000), vol. 32, no. P4396, P4409, pages 784; - 785; 788, XP055751748-
OPPOSITION- Lang Chim C, Struthers Allan D., "Targeting the renin-angiotensin-aldosterone system in heart failure", Nature Reviews Cardiology, (20130301), vol. 10, pages 125 - 134, XP055788520-
OPPOSITION- Luchner Andreas, Et Al, "Bedeutung der Herzinsuffizienzmarker BNP und NT-proBNP für die Klinik", Deutsches Arzteblatt, (20031212), vol. 100, no. 50, pages A3314 - A3321, XP055788524-
OPPOSITION- Milton Packer, Robert M. Califf, Md; Marvin A. Konstam, Md; Henry Krum, Mbbs, Phd; John J. Mcmurray, Md; Jean-Lucien Rouleau, Md; Karl Swedberg, "Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure", Circulation, (20020820), vol. 106, no. 8, pages 920 - 926, XP055767134-
OPPOSITION- Mutschler, "Arzneimittelwirkungen. 10th Ed. Passage Chapter 34: Therapie der Herzinsuffizienz", Wissenschaftliche Verlagsgesellschaft, Stuttgart, Stuttgart, (20200101), pages 1 - 2, 435, (20210607), XP055810985-
OPPOSITION- Mutschler, Arzneimittelwirkungen. Chapter Herzinsuffizienz. 10th Ed., Stuttgart, Wissenschaftliche Verlagsgesellschaft, (20130101), pages 1 - 8, XP055810964-
OPPOSITION- Mutschler H.C. Ernst, Et Al, "Mutschler Arzneimittelwirkungen Lehrbuch der Pharmakologie und Toxikologie. Passage", (20010101), pages 120 - 124, XP055780128-
OPPOSITION- Pfeffer Marc A, Et Al, "Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both", The New England Journal of Medicine, Massachusetts Medical Society, (20031113), vol. 349, no. 20, pages 1893 - 1906, XP055791018-
OPPOSITION- Z. Kobalava, Averkov O. , Meray I. , Alexandriya L. , Moiseev V. , Albrecht D. , Feng A. , Chandra P. , Jordaan P.J., "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: Effect on ANP, BNP, NT-proBNP and cGMP", European Heart Journal, (20110000), vol. 32, no. P4396, P4409, pages 784, - 785, 788, XP055751748-
OPPOSITION- Z. Kobalava, Averkov O. , Meray I. , Alexandriya L. , Moiseev V. , Albrecht D. , Feng A. , Chandra P. , Jordaan P.J., "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: Effect on ANP, BNP, NT-proBNP and cGMP", European Heart Journal, (20110101), vol. 32, no. P4396, P4409, page 788, XP055751748-
OPPOSITION- Z. Kobalava, Averkov O. , Meray I. , Alexandriya L. , Moiseev V. , Albrecht D. , Feng A. , Chandra P. , Jordaan P.J., "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: Effect on ANP, BNP, NT-proBNP and cGMP", European Heart Journal, (20110101), vol. 32, no. P4396, P4409, pages 784; - 785; 788, XP055751748-
OPPOSITION- Z. Kobalava, Averkov O. , Meray I. , Alexandriya L. , Moiseev V. , Albrecht D. , Feng A. , Chandra P. , Jordaan P.J., "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: Effect on ANP, BNP, NT-proBNP and cGMP", European Heart Journal, (20110101), vol. 32, no. P4396, P4409, pages 784 - 785, XP055751748-
OPPOSITION- Z. Kobalava, Averkov O. , Meray I. , Alexandriya L. , Moiseev V. , Albrecht D. , Feng A. , Chandra P. , Jordaan P.J., "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: Effect on ANP, BNP, NT-proBNP and cGMP", European Heart Journal, (20110101), vol. 32, no. P4396, P4409, pages 784; - 785;, XP055751748-
OPPOSITION- Gustafsson, F. Steensgaard-Hansen, F. Badskjaer, J. Poulsen, A.H. Corell, P. Hildebrandt, P., "Diagnostic and Prognostic Performance of N-Terminal ProBNP in Primary Care Patients With Suspected Heart Failure", JOURNAL OF CARDIAL FAILURE, US, (20050601), vol. 11, no. 5, doi:10.1016/j.cardfail.2005.04.022, ISSN 1071-9164, pages S15 - S20, XP004929813
OPPOSITION- Thomas H. Langenickel, William P.Dole, "Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure", Drug Discovery Today: Therapeutic Strategies, (20120000), vol. 9, no. 4, pages e131 - e139, XP055751770
OPPOSITION- Thomas H.Langenickel, William P.Dole, "Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure", Drug Discovery Today: Therapeutic Strategies, (20120000), vol. 9, no. 4, pages e131 - e139, XP055751770
OPPOSITION- Thomas H. Langenickel, William P.Dole, "Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure", Drug Discovery Today: Therapeutic Strategies, doi:10.1016/j.ddstr.2013.11.002, (20120101), pages e131 - e139, Drug Discovery Today: Therapeutic Strategies, (20201118), XP055751770
OPPOSITION- C. W. YANCY et al., "2013 ACCF/AHA Guideline for the Management of Heart Failure", Journal of the American College of Cardiology, (20130605), vol. 62, no. 16, doi:10.1016/j.jacc.2013.05.019, pages e147 - e239, XP028733857
OPPOSITION- ARONSON et al., "Novel therapies in acute and chronic heart failure", Pharmacology & Therapeutics, (20120000), vol. 135, doi:10.1016/j.pharmthera.2012.03.002, pages 1 - 17, XP028503167
OPPOSITION- Doron Aronson; Henry Krum, "Novel therapies in acute and chronic heart failure", Pharmacology and Therapeutics, (20120000), vol. 135, doi:10.1016/j.pharmthera.2012.03.002, pages 1 - 17, XP028503167
OPPOSITION- Doron Aronson; Henry Krum;, "Novel therapies in acute and chronic heart failure", PHARMACOLOGY AND THERAPEUTICS., ELSEVIER., GB, GB, (20120701), vol. 135, no. 1, doi:10.1016/j.pharmthera.2012.03.002, ISSN 0163-7258, pages 1 - 17, XP028503167
OPPOSITION- Ruilope, L.M. ; Dukat, A. ; Bohm, M. ; Lacourciere, Y. ; Gong, J. ; Lefkowitz, M.P., "Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study", Lancet, (20100000), vol. 375, no. 9722, pages 1255 - 1266, XP027490781
OPPOSITION- Ruilope L M; Dukat A; Bohm M; Lacourciere Y; Gong J; Lefkowitz M P, "Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study", The Lancet, (20100000), vol. 375, no. 9722, pages 1255 - 1266, XP027490781
OPPOSITION- Ruilope, L.M. ; Dukat, A. ; Bohm, M. ; Lacourciere, Y. ; Gong, J. ; Lefkowitz, M.P., "Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study", The Lancet, AMSTERDAM, NL, (20100410), vol. 375, no. 9722, doi:10.1016/S0140-6736(09)61966-8, ISSN 0140-6736, pages 1255 - 1266, XP027490781
OPPOSITION- Scott D Solomon, Michael Zile, Burkert Pieske, Adriaan Voors, Amil Shah, Elisabeth Kraigher-Krainer, Victor Shi, Toni Bransford, Madoka Takeuchi, Jianjian Gong, Martin Lefkowitz, Milton Packer, John Jv Mcmurray, "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial", Lancet, (20120000), vol. 380, no. 9851, pages 1387 - 1395, XP055083562
OPPOSITION- Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John Jv Mcmurray, "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial", Lancet, (20120000), vol. 380, no. 9851, pages 1387 - 1395, XP055083562
OPPOSITION- Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John Jv Mcmurray, "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial", Lancet, (20121020), vol. 380, doi:10.1016/S0140-6736(12)61227-6, pages 1387 - 1395, XP055083562
OPPOSITION- Scott D Solomon, Michael Zile, Burkert Pieske, Adriaan Voors, Amil Shah, Elisabeth Kraigher-Krainer, Victor Shi, Toni Bransford, Madoka Takeuchi, Jianjian Gong, Martin Lefkowitz, Milton Packer, John Jv Mcmurray, "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial", The Lancet, (20121001), vol. 380, no. 9851, doi:10.1016/S0140-6736(12)61227-6, ISSN 01406736, pages 1387 - 1395, XP055083562
OPPOSITION- Scott D Solomon, Michael Zile, Burkert Pieske, Adriaan Voors, Amil Shah, Elisabeth Kraigher-Krainer, Victor Shi, Toni Bransford, Madoka Takeuchi, Jianjian Gong, Martin Lefkowitz, Milton Packer, John Jv Mcmurray, "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial", The Lancet, J.B. Flint|, (20121001), vol. 380, no. 9851, doi:10.1016/S0140-6736(12)61227-6, ISSN 01406736, pages 1387 - 1395, XP055083562
OPPOSITION- Scott D Solomon, Michael Zile, Burkert Pieske, Adriaan Voors, Amil Shah, Elisabeth Kraigher-Krainer, Victor Shi, Toni Bransford, Madoka Takeuchi, Jianjian Gong, Martin Lefkowitz, Milton Packer, John Jv Mcmurray, "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial", The Lancet, �J.B. Flint|, (20121001), vol. 380, no. 9851, doi:10.1016/S0140-6736(12)61227-6, ISSN 01406736, pages 1387 - 1395, XP055083562
OPPOSITION- O Vardeny, T Tacheny, S D Solomon, "First-in-Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure", Clinical Pharmacology and Therapeutics, US, (20131001), vol. 94, no. 4, doi:10.1038/clpt.2013.146, ISSN 0009-9236, pages 445 - 448, XP055224441
OPPOSITION- O Vardeny, T Tacheny, S D Solomon, "First-in-Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure", Clinical Pharmacology & Therapeutics, (20130000), vol. 94, no. 4, pages 445 - 448, XP055224441
OPPOSITION- Vardeny O; Tacheny T; Solomon S D, "First-in-Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure", Clinical Pharmacology & Therapeutics, (20130000), vol. 94, no. 4, pages 445 - 448, XP055224441
OPPOSITION- COHN et al., "A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure", The New England Journal of Medicine, (20010000), vol. 345, no. 23, doi:10.1056/NEJMoa010713, pages 1667 - 1675, XP009033568
OPPOSITION- Chi Heem Wong; Kien Wei Siah; Andrew W Lo, "Estimation of clinical trial success rates and related parameters", Biostatistics, (20190000), vol. 20, no. 2, doi:10.1093/biostatistics/kxx069, pages 273 - 286, XP055604937
OPPOSITION- Chi Heem Wong, Kien Wei Siah, Andrew W Lo, "Estimation of clinical trial success rates and related parameters", Biostatistics, Oxford university press , Oxford, GB, GB, (20190430), vol. 20, no. 2, doi:10.1093/biostatistics/kxx069, ISSN 1465-4644, pages 273 - 286, XP055604937
OPPOSITION- J. J. V. Mcmurray, S. Adamopoulos, S. D. Anker, A. Auricchio, M. Bohm, K. Dickstein, V. Falk, G. Filippatos, C. Fonseca, M. A. Gomez-Sanchez, T. Jaarsma, L. Kober, G. Y. H. Lip, A. P. Maggioni, A. Parkhomenko, B. M. Pieske, B. A. Popescu, P. K. Ronnevik, F. H. Rutten, J. Schwitter, P. Seferovic, J. Stepinska, P. T. Trindade, A. A. Voors, F. Zannad, A. Zeiher, J. J. Bax, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, T. Mcdonagh, C. Moulin, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, A. Vahanian, S. Windecker, L. A. Bonet, P. Avraamides, H. A. Ben Lamin, M. Brignole, A. Coca, P. Cowburn, H. Dargie, P. Elliott, F. A. Flachskampf, G. F. Guida, S. Hardman, B. Iung, B. Merkely, C. Mueller, J. N. Nanas, O. W. Nielsen, S. Orn, J. T. Parissis, P. Ponikowski, "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC", European Heart Journal, (20120702), vol. 33, no. 14, doi:10.1093/eurheartj/ehs104, ISSN 0195668X, pages 1787 - 1847, XP055140708
OPPOSITION- John J V Mcmurray; Milton Packer; Akshay S Desai; Jim Gong; Martin P Lefkowitz; Adel R Rizkala; Jean Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact", EUROPEAN JOURNAL OF HEART FAILURE, (20130405), vol. 15, no. 9, ISSN 1388-9842, pages 1062 - 1073, XP055161544
OPPOSITION- John J. V. Mcmurray, Milton Packer, Akshay S. Desai, Jim Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean Rouleau, Victor C. Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact", EUROPEAN JOURNAL OF HEART FAILURE, NL, (20130901), vol. 15, no. 9, doi:10.1093/eurjhf/hft052, ISSN 1388-9842, pages 1062 - 1073, XP055161544
OPPOSITION- John J. V. Mcmurray, Milton Packer, Akshay S. Desai, Jim Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean Rouleau, Victor C. Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, NL, (20130901), vol. 15, no. 9, doi:10.1093/eurjhf/hft052, ISSN 1388-9842, pages 1062 - 1073, XP055161544
OPPOSITION- MCMURRAY et al., "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF", European Journal of Heart Failure, (20130000), vol. 15, pages 1062 - 1073, XP055161544
OPPOSITION- MCMURRAY et al., European Journal of Heart Failure, (20130000), vol. 15, pages 1062 - 1073, XP055161544
OPPOSITION- Zouein F A; De Castro Bras L E; Da Costa D V; Lindsey M L; Kurdi M; Booz G, "Heart failure with preserved ejection fraction: Emerging drug strategies", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, US, (20130701), vol. 62, no. 1, doi:10.1097/FJC.0b013e31829a4e61, ISSN 0160-2446, pages 13 - 21, XP009173459
OPPOSITION- Von Lueder, Et Al, "Renin-Angiotensin Blockade Combined with Natriuretic Peptide System Augmentation", Circ. Heart Fail, (20130101), vol. 6, doi:10.1161/CIRCHEARTFAILURE.112.000289, pages 594 - 605, XP055780114
OPPOSITION- GU et al., "Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual- acting angiotensin receptor-neprilysin inhibitor (ARNi", Journal of Clinical Pharmacology, (20100000), vol. 50, doi:10.1177/0091270009343932, pages 401 - 414, XP002718352
OPPOSITION- Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel D F, Jeng A Y, Lin T H, Zheng W, Dole W P, "Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).", Journal of clinical pharmacology, US, (20100401), vol. 50, no. 4, doi:10.1177/0091270009343932, ISSN 1552-4604, pages 401 - 414, XP002718352
OPPOSITION- Voors A A; Dorhout B; Van Der Meer P, "The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure", EXPERT OPINION ON INVESTIGATIONAL DRUGS, LONDON, GB, (2013), vol. 22, no. 8, ISSN 1354-3784, pages 1041 - 1047, XP009173461
OPPOSITION- Voors A A; Dorhout B; Van Der Meer P, "The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure", Expert Opinion on Investigational Drugs, UK, (20130101), vol. 22, no. 8, doi:10.1517/13543784.2013.797963, ISSN 1354-3784, pages 1041 - 1047, XP009173461

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents